MENU
+Compare
OVID
Stock ticker: NASDAQ
AS OF
Sep 17, 04:59 PM (EDT)
Price
$1.15
Change
+$0.01 (+0.88%)
Capitalization
81.06M

OVID Ovid Therapeutics Forecast, Technical & Fundamental Analysis

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders... Show more

OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for OVID with price predictions
Sep 16, 2025

OVID sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for OVID moved above the 200-day moving average on August 29, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

OVID may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 165 cases where OVID Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for OVID moved out of overbought territory on September 16, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where OVID's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on September 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on OVID as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for OVID turned negative on September 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.453) is normal, around the industry mean (20.607). P/E Ratio (0.000) is within average values for comparable stocks, (53.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.160). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (12.180) is also within normal values, averaging (333.412).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

OVID is expected to report earnings to rise 135.67% to -14 cents per share on November 12

Ovid Therapeutics OVID Stock Earnings Reports
Q3'25
Est.
$-0.14
Q2'25
Beat
by $0.10
Q1'25
Est.
$-0.14
Q4'24
Beat
by $0.04
Q3'24
Beat
by $0.01
The last earnings report on August 13 showed earnings per share of -5 cents, beating the estimate of -15 cents. With 631.73K shares outstanding, the current market capitalization sits at 81.06M.
A.I. Advisor
published General Information

General Information

Provides medicines to children and adults with neurological disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
441 Ninth Avenue
Phone
+1 646 661-7661
Employees
40
Web
https://www.ovidrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HYPMY4.600.36
+8.49%
Hypera SA
SVMLF0.46N/A
+0.43%
Sovereign Metals Ltd.
PFBN8.65N/A
N/A
Pacific Alliance Bank (CA)
RICFY15.47N/A
N/A
Recordati Industria Chimica e Farmaceutica S.p.A.
OTRKQ0.03-0.01
-28.33%
Ontrak, Inc.

OVID and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-10.94%
JBIO - OVID
79%
Closely correlated
+0.99%
ARCT - OVID
45%
Loosely correlated
-0.22%
GBIO - OVID
43%
Loosely correlated
+6.44%
DNLI - OVID
42%
Loosely correlated
+0.76%
ABOS - OVID
42%
Loosely correlated
-2.38%
More

Groups containing OVID

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-10.94%
OVID
(2 stocks)
11%
Poorly correlated
-0.89%